Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 4/16/2024

1. GS
2. JNJ
3. SPY
4. BK
5. UNH

6. SCHW
7. MS
8. TSLA
9. MSFT
10. BAC

Get Alerts ITCI Hot Sheet

Price: $64.76 --0%

Overall Analyst Rating:
BUY (

Up)

EPS Growth %: +28.3%

Join SI Premium – FREE

NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, November 5, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2019.

To access the live conference call via phone, dial 1-(844) 835-6563 The International dial-in number is 1-(970) 315-3916. The conference ID number for the live call is 5756327.

The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone is under review by the FDA for the treatment of schizophrenia and is in Phase 3 clinical development for the treatment of bipolar depression. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and for the treatment of heart failure.

Contact:

Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333

Burns McClellan, Inc. Lisa Burns [email protected] 212-213-0006

Source: Intra-Cellular Therapies Inc.